We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Published in Lung Cancer

Journal Scan / Research · March 11, 2021

Ramucirumab With Osimertinib in Advanced T790M-Positive EGFR-Mutant NSCLC

Clinical Cancer Research


Additional Info

Clinical Cancer Research
Phase I Study of the Efficacy and Safety of Ramucirumab in Combination With Osimertinib in Advanced T790M-Positive EGFR-Mutant Non–Small Cell Lung Cancer
Clin. Cancer Res 2021 Feb 15;27(4)992-1002, HA Yu, LG Paz-Ares, JC Yang, KH Lee, P Garrido, K Park, JH Kim, DH Lee, H Mao, SR Wijayawardana, L Gao, RR Hozak, BH Chao, D Planchard

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading